Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel hypothesis for stroke prediction, introducing CHA<sub>2</sub>DS<sub>2</sub>-VAScF.

Current medical research and opinion·2026
Same author

Including Vonoprazan With PPIs Challenges the Drug-Interaction Hypothesis.

JACC. Asia·2026
Same author

Finerenone, New-Onset Atrial Fibrillation, and Prognosis in HFpEF/HFmrEF.

JAMA cardiology·2026
Same author

Methodological concerns in the OASIS-HF study: phenotypic misclassification and selection bias.

ESC heart failure·2026
Same author

Preventing stroke or myocardial infarction?: The new monotherapy crossroads in atrial fibrillation and coronary artery disease.

The American journal of medicine·2026
Same author

Letter: Beta blocker withdrawal post-MI - the missed dimension of patient symptoms.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Related Experiment Videos

Hypertension management: is lower always better?

Ahmed B Shamsulddin1

  • 1- ahmbah10@gmail.com.

Minerva Medica
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Lowering blood pressure targets can reduce cardiovascular events, especially for high-risk patients. However, a personalized approach is crucial, considering individual factors and potential harms, moving beyond a one-size-fits-all strategy.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Background:

  • Systemic arterial hypertension is a major cause of cardiovascular mortality.
  • Global guidelines differ on optimal blood pressure targets (e.g., <130/80 mmHg vs. <140/90 mmHg).
  • The debate continues on whether lower blood pressure targets are universally beneficial.

Purpose of the Study:

  • To review evidence on intensive versus conservative blood pressure targets in hypertension management.
  • To evaluate the benefits and risks associated with lower blood pressure targets.
  • To explore personalized approaches to hypertension treatment.

Main Methods:

  • Narrative review synthesizing data from landmark trials (SPRINT, STEP, ESPRIT, STOP-Trial, CREOLE, TOPSPIN).
  • Analysis of cardiovascular event reduction, mortality, and adverse events.
  • Examination of factors influencing therapeutic efficacy, including patient risk, ethnicity, and geography.

Main Results:

  • Intensive systolic blood pressure control (<120-130 mmHg) reduces cardiovascular events and mortality in high-risk individuals.
  • Lower targets increase risks of hypotension and acute kidney injury; long-term benefits require further study.
  • Evidence suggests therapeutic efficacy varies by ethnicity and geography, challenging a universal approach.

Conclusions:

  • Intensive blood pressure control benefits high-risk hypertensive patients but is not universally mandated.
  • A personalized medicine approach, using pharmacogenomics and population-specific strategies, is essential for optimal hypertension management.
  • Future guidelines should aim for personalized blood pressure targets rather than a single numerical goal.